T
Taysha Gene Therapies, Inc. (TSHA)
NMS – Real Time Price. Currency in USD
6.34
+0.13 (2.09%)
At close: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
6.34
+0.13 (2.09%)
At close: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Name | Position |
|---|---|
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary |
| Mr. Sean McAuliffe | Chief Business Officer |
| Mr. Sean P. Nolan | CEO & Chairman |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer |
| Ms. Rumana Haque-Ahmed | Chief Regulatory Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-22 | 8-K | d20817d8k.htm |
| 2026-06-02 | 8-K | d159199d8k.htm |
| 2026-05-06 | 8-K | d99032d8k.htm |
| 2026-05-06 | 10-Q | tsha-20260331.htm |
| 2026-04-22 | DEFA14A | d139508ddefa14a.htm |
| 2026-04-22 | DEF 14A | d94391ddef14a.htm |
| 2026-04-22 | ARS | d942601dars.pdf |
| 2026-03-19 | 8-K | d46409d8k.htm |
| 2026-03-19 | 10-K | tsha-20251231.htm |
| 2026-01-06 | S-8 | d20072ds8.htm |